Patent · US Active

Anti-TNFα antibodies with pH-dependent antigen binding for improved target clearence

US10183994B2 · kind B2 · utility

0Cited by

1References

22Claims

0Family size

Assignee

Merck Patent GmbH · DE

Inventors

Ralf Guenther · Griesheim, DE
Stefan Becker · Darmstadt, DE
Laura Rhiel · Frankfurt am Main, DE
Bjoern Hock · Maintal, DE
Christian Schroeter · Bamberg, DE

Key dates

Filing date	Jun 26, 2015
Grant date	Jan 22, 2019
Priority date	—
Expiry date	Jun 26, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to anti-TNFα antibodies which are engineered to exhibit a pH-sensitive antigen binding. The invention is preferably directed to anti-TNFα antibody adalimumab (Humira®) or biologically active variants and fragments thereof, wherein the original adalimumab antibody or variant or fragment thereof is engineered by modifications of amino acid sequence within the variable regions. Specifically, the invention relates to adalimumab or biologically active variants or fragments thereof, wherein the CDR domains are modified by replacing one or more amino acid residues by histidine residues.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.